相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Increased expression of ADAM12 and ADAM17 genes in laser-capture microdissected breast cancers and correlations with clinical and pathological characteristics
Diana Narita et al.
ACTA HISTOCHEMICA (2012)
Genotypic and Phenotypic Characterization of Side Population of Gastric Cancer Cell Lines
Rosa Schmuck et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNFα/NFκB pathway
Hanan Armanious et al.
BLOOD (2011)
Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression
J-W Kornfeld et al.
BRITISH JOURNAL OF CANCER (2011)
Oncogenic Kras Promotes Chemotherapy-Induced Growth Factor Shedding via ADAM17
Sandra Van Schaeybroeck et al.
CANCER RESEARCH (2011)
Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors
Stephen I. Rudnick et al.
CANCER RESEARCH (2011)
ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers
G. Sinnathamby et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2011)
The A Disintegrin And Metalloproteases ADAM10 and ADAM17: Novel drug targets with therapeutic potential?
Paul Saftig et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2011)
Inhibition of the Inflammatory Cytokine TNF-α Increases Adenovirus Activity in Ovarian Cancer via Modulation of cIAP1/2 Expression
Michael A. Salako et al.
MOLECULAR THERAPY (2011)
Cross-domain inhibition of TACE ectodomain
Christopher J. Tape et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17
Thorsten Maretzky et al.
NATURE COMMUNICATIONS (2011)
Guidelines for the welfare and use of animals in cancer research
P. Workman et al.
BRITISH JOURNAL OF CANCER (2010)
ADAM17 Regulates Epidermal Growth Factor Receptor Expression through the Activation of Notch1 in Non-Small Cell Lung Cancer
Anja Baumgart et al.
CANCER RESEARCH (2010)
Pathological Neovascularization Is Reduced by Inactivation of ADAM17 in Endothelial Cells but Not in Pericytes
Gisela Weskamp et al.
CIRCULATION RESEARCH (2010)
Expression Profiles and Clinical Correlations of Degradome Components in the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma
Angela Stokes et al.
CLINICAL CANCER RESEARCH (2010)
Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer
Joan N. Kyula et al.
CLINICAL CANCER RESEARCH (2010)
HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
Merel Gijsen et al.
PLOS BIOLOGY (2010)
Involvement of a disintegrin and metalloproteinase 10 and 17 in shedding of tumor necrosis factor-α
Atsuhiko Hikita et al.
BIOCHEMISTRY AND CELL BIOLOGY (2009)
ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation
Xuguang Zheng et al.
CANCER BIOLOGY & THERAPY (2009)
Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: coexpression with EGFR and EGFR ligands
Motomichi Nakagawa et al.
CANCER SCIENCE (2009)
Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblasts
Renata Mezyk-Kopec et al.
CYTOKINE (2009)
Transcription factor Sp1 induces ADAM17 and contributes to tumor cell invasiveness under hypoxia
Alexandra Szalad et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2009)
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer
E. R. Brown et al.
ANNALS OF ONCOLOGY (2008)
Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor
Lois Witters et al.
CANCER RESEARCH (2008)
VEGF-A Stimulates ADAM17-Dependent Shedding of VEGFR2 and Crosstalk Between VEGFR2 and ERK Signaling
Steven Swendeman et al.
CIRCULATION RESEARCH (2008)
Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis
Marcia L. Moss et al.
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2008)
The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells
Ombretta Rosso et al.
MOLECULAR CANCER RESEARCH (2007)
Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor α-converting enzyme in rodents, dogs, chimpanzees, and humans
Mingxin Qian et al.
DRUG METABOLISM AND DISPOSITION (2007)
Post-transcriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast turnors
Belen Santiago-Josefat et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer
Jordan S. Fridman et al.
CLINICAL CANCER RESEARCH (2007)
The inflammatory cytokine tumor necrosis factor-α generates an autocrine tumor-promoting network in epithelial ovarian cancer cells
Hagen Kulbe et al.
CANCER RESEARCH (2007)
Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-α converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma
Joerg Ringel et al.
CANCER RESEARCH (2006)
Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17
Aleksandra Franovic et al.
CANCER RESEARCH (2006)
A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinurn containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study
H. Hirte et al.
GYNECOLOGIC ONCOLOGY (2006)
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
Bin-Bing S. Zhou et al.
CANCER CELL (2006)
Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human
Claudia Bossen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Adam meets Eph:: An ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans
PW Janes et al.
CELL (2005)
Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells
F Blanchot-Jossic et al.
JOURNAL OF PATHOLOGY (2005)
Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer
S Madhusudan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer
D Bissett et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Increased expression of ADAM family members in human breast cancer and breast cancer cell lines
U Lendeckel et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2005)
Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group Trial E2196
JA Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Evaluation of the contribution of different ADAMs to tumor necrosis factor α (TNFα) shedding and of the function of the TNFα ectodomain in ensuring selective stimulated shedding by the TNFα convertase (TACE/ADAM17)
YF Zheng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Binding and functional comparisons of two types of tumor necrosis factor antagonists
B Scallon et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies
RJ Ober et al.
INTERNATIONAL IMMUNOLOGY (2001)
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors
EI Heath et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
Full-length and N-TIMP-3 display equal inhibitory activities toward TNF-α convertase
MH Lee et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
S Zucker et al.
ONCOGENE (2000)
分享论文
